Novavax Inc.’s stock soared 51% Tuesday after the biotech company reported positive results from a trial of three flu and COVID vaccines and unveiled a restructuring that will see it part with a quarter of its staff.
The move put the stock on track for its biggest one-day gain in more than two years as worries raised by the company’s “going-concern” warning from earlier this year appeared to ease.
For…
